Small-cap biotechs are easy to dismiss. Most fail. But every so often, a company produces the kind of clinical data that makes you stop and take a second look. Medicus Pharma (NASDAQ: MDCX) may be one of those companies right now.
In the span of just a few weeks, Medicus announced positive topline Phase 2 results for its skin cancer treatment and received FDA clearance to begin a Phase 2b trial in prostate cancer. For a company this size, that is a meaningful amount of progress in a short window.
A patch that fights skin cancer without surgery
The most talked-about development is SkinJect, Medicus’ dissolvable microneedle patch that delivers doxorubicin, a well-established chemotherapy drug, directly into basal cell carcinoma tumors. The pitch is simple: treat the most common cancer in the world without a scalpel.
The company just reported topline results from its Phase 2 SKNJCT-003 study, which enrolled 90 patients across nine U.S. sites in a randomized, double-blind, placebo-controlled trial. In the highest-dose group (200µg), 73% of treated lesions achieved clinical clearance at Day 57, meaning the tumor visually disappeared. Histological clearance, the more stringent measure requiring no tumor cells on biopsy, came in at 40%.
To put that in context, the placebo arm used the same microneedle device without the drug and achieved 38% clinical clearance. That gap matters. It tells you the drug itself is contributing meaningfully on top of whatever mechanical effect the device produces. That is the signal investors and regulators need to see.
Clearance rates also continued to rise between Day 29 and Day 57, which the company believes reflects ongoing biological activity. That trend could support longer treatment intervals or additional dosing sessions in a future Phase 3 design.
The full Clinical Study Report is expected in Q2 2026, and Medicus plans to request an End-of-Phase 2 meeting with the FDA in the first half of the year. A favorable outcome would put the company on a clear path toward a registrational trial and, more importantly, serious conversations with potential licensing partners.
A prostate cancer drug with a cardiovascular edge
The second piece of the story is Teverelix, a long-acting injectable GnRH antagonist that Medicus acquired through its August 2025 purchase of UK-based Antev. The drug targets men with advanced prostate cancer, but with a specific twist that sets it apart from existing options.
Most hormone therapies for prostate cancer work by suppressing testosterone. The older class of drugs, GnRH agonists, do this by first triggering a surge in testosterone before suppressing it. That flare can be dangerous for patients with existing heart disease. GnRH antagonists like Teverelix bypass the flare entirely, suppressing sex hormones directly and immediately.
Why does that matter? Cardiovascular disease kills roughly 30% of prostate cancer patients, more than many people realize. Men with pre-existing heart conditions who are treated with GnRH agonists face a dramatically higher risk of major cardiac events compared to those on antagonists. Teverelix is being developed specifically for this high-risk population, with a cardiovascular-risk-focused label that would be a first in the field if approved.
On February 10, 2026, the FDA granted ‘study may proceed’ clearance for a Phase 2b dose-optimization trial in 40 advanced prostate cancer patients. The company has also received FDA approval for a separate Phase 2b trial in acute urinary retention relapse covering 390 patients. Together, the two indications represent an estimated $6 billion in addressable market opportunity.
The business model: de-risk and partner
Medicus is not trying to become a fully integrated pharmaceutical company. Its stated strategy is to advance programs through Phase 2 proof-of-concept, then license or partner with established pharma companies for late-stage development and commercialization. That model keeps costs down, reduces dilution, and creates clean value-inflection points for investors.
The company is also pursuing an AI-driven clinical analytics platform through a letter of intent with Reliant AI, aimed at improving site selection and patient enrollment for upcoming trials. It is a small but interesting sign that management is thinking carefully about capital efficiency.
What to watch
-SkinJect full Clinical Study Report, expected Q2 2026
-End-of-Phase 2 FDA meeting for SkinJect, planned H1 2026
-Teverelix Phase 2b prostate cancer trial initiation in 2026
-Teverelix AURr Phase 2b enrollment (390 patients)
Any licensing or partnership announcements across either program
None of this is a sure thing. Phase 2 data doesn’t guarantee Phase 3 success, and small biotechs carry real binary risk. But Medicus has two programs generating real clinical signals, a lean operating model, and a pipeline of near-term catalysts that could meaningfully move the stock. For investors comfortable with biotech risk, it’s worth putting on your watchlist.